<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721106</url>
  </required_header>
  <id_info>
    <org_study_id>A7471060</org_study_id>
    <nct_id>NCT04721106</nct_id>
  </id_info>
  <brief_title>Korea Post Marketing Surveillance (PMS) Study of Vizimpro</brief_title>
  <official_title>A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Vizimpro(Registered)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vizimpro will be approved for the treatment of EGFR NSLCL 1L in Korea. In accordance with the&#xD;
      Standards for Re-examination of New Drug, it is required to conduct a PMS. Post marketing&#xD;
      surveillance is required to determine any problems or questions associated with Vizimpro&#xD;
      after marketing in Korea, with regard to the following clauses under conditions of general&#xD;
      clinical practice. Therefore, through this study, effectiveness and safety of Vizimpro will&#xD;
      be observed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 7, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events categorized according to physical organ and disease/symptom</measure>
    <time_frame>From Day 1 of first administration dose up to the date of at least 28 calendar days following the last administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>Day 1 until progression or drop out of study</time_frame>
    <description>This study is observation, non-intervention study in routine clinical practice. Response rate according to RECIST criteria will be collected under routine clinical practice visit.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>Vizimpro treatment group</arm_group_label>
    <description>This group is included the patients that Vizimpro are prescribed and administrated according to local label in the routine clinical practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vizimpro</intervention_name>
    <description>treatment group</description>
    <arm_group_label>Vizimpro treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients to whom Vizimpro can be prescribed as per the local labeling (the first-line&#xD;
        treatment of adult patients with locally advanced or metastatic NSCLC with epidermal growth&#xD;
        factor receptor EGFR-activating mutations&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must meet all of the following inclusion criteria to be eligible for inclusion in&#xD;
        the study:&#xD;
&#xD;
          1. Vizimpro速 na誰ve patients to whom Vizimpro速 can be prescribed as per the local labeling&#xD;
             (the first-line treatment of adult patients with locally advanced or metastatic&#xD;
             non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon&#xD;
             19 deletion or exon 21 L858R substitution mutations&#xD;
&#xD;
          2. Evidence of a signed and dated informed consent document indicating that the patient&#xD;
             (or a legally acceptable representative) has been informed of all pertinent aspects of&#xD;
             the study&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Patients meeting any of the following criteria will not be included in the study:&#xD;
&#xD;
          1. Patients to whom Vizimpro速 is contraindicated as per the local labeling. A.&#xD;
             Hypersensitivity to the active substance or to any of the excipients of this product.&#xD;
&#xD;
             B. This medicinal product contains lactose. Patients with rare hereditary conditions&#xD;
             of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption&#xD;
             should not take this medicinal product.&#xD;
&#xD;
          2. Any patients (or a legally acceptable representative) who does not agree that Pfizer&#xD;
             and companies working with Pfizer use his/her information.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A7471060</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

